AstraZeneca PLC July 2025 Financial Report: Key Voting Rights Insights

Here are the key insights extracted from the financial report (Form 6-K) for AstraZeneca PLC:

1. Company Details:

• Name: AstraZeneca PLC
• Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom
• Commission File Number: 001-11960

2. Reporting Period:

• The report covers the month of July 2025.

3. Total Voting Rights:

• As of 30 June 2025, AstraZeneca has 1,550,670,668 ordinary shares with voting rights, each with a nominal value of US$0.25.
• No shares are held in Treasury, meaning all shares are available for voting.

4. Regulatory Compliance:

• This report serves as a notification under the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.
• The total number of voting rights is relevant for shareholders to determine if they need to notify their interest in AstraZeneca under applicable rules.

5. Shareholder Considerations:

• The total voting rights figure can be used by shareholders as a denominator for calculations related to their interests in the company.

6. Company Overview:

• AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in areas such as Oncology and Rare Diseases.

7. Contact Information:

• The report includes information on how to contact the Investor Relations Team and Media contacts.

8. Signature:

• The report has been signed by Adrian Kemp, the Company Secretary, confirming the contents of the report.

This document provides essential information for stakeholders regarding AstraZeneca's voting rights and compliance with regulatory requirements, which is crucial for governance and investor relations.